Lundbeck invests in Ossianix; VaxyGen considers Atlanta as new HQ site; CRO fined for record doctoring;

@FierceBiotech: FDA dishes out long-awaited guidance on social media. Article | Follow @FierceBiotech

@JohnCFierce: In case you missed last week's news, Alexion scoops up promising rare disease drug in $1.08B Enobia buyout. Story | Follow @JohnCFierce

@RyanMFierce: Accelrys paying $35M cash in VelQuest buyout, expanding from R&D software to tech for drug manufacturers. Release | Follow @RyanMFierce

> Philadelphia-based Ossianix says that Lundbeck has made an unspecified investment in the biotech as investigators use its antibody platform modeled on the shark vNAR structure to find new drug candidates. Release

> The vaccine startup VaxyGen is considering putting its headquarters in Atlanta, promising to create up to 250 jobs. Report

> The data software firm Accelrys is buying VelQuest for $35 million. Story

> PPS Clinical Research reportedly paid a $68,000 fine and pleaded guilty to a federal obstruction charge after acknowledging an employee at the CRO had doctored patient records for clinical trial work on Boehringer Ingelheim's Flibanserin, a "female Viagra" drug shot down last year by an expert panel. Chesterfield, MO-based PPS also paid $206,000 to settle a civil case. Story

Pharma News

@FiercePharma: Bristol will have a tough time replacing 'string of pearls' strategist Levin, Bloomberg says. Story | Follow @FiercePharma

> FDA: No off-label sharing in social media. More

> Teva lures Levin to repeat BMS dealmaking. Report

> DEA quotas allow ADHD generics to run short. Report

Pharma Manufacturing News

> Flu vax tool aids strain identification, timing. Story

> Hospira enters angry-investor phase of remediation. Article

> Ben Venue lengthens remediation timeline. Item

> Infant pain reliever dosing 'fix' shows label limitations. Report

> Rockline quietly recalls contaminated wipes. News

> H&P/Triad, under decree, will recondition seized wipes. More

Biotech Research News

> Fish oil wipes out leukemia in mice. News

> Researchers decode some kidney cancer secrets. Item

> Johns Hopkins tapping genomes to find out why so many African-Americans get asthma. News

Biotech IT News

> FDA dishes out long-awaited guidance on social media. Article

> Poor patient recruitment cited in call for trial disclosures. Story

And Finally... Penn State scientists have discovered that a compound derived from fish oil targets and kills leukemia stem cells in the spleen and bone marrow in mice, completely wiping out the disease with minimal side effects, according to an article on the academic research news site Futurity.org. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.